DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Norovirus” report has been added to ResearchAndMarkets.com’s
offering.
This Market Spotlight report covers the Norovirus market, comprising key
pipeline drugs, clinical trials, probability of success, key upcoming
events, and an epidemiological overview.
Key Takeaways
-
Worldwide, about one out of every five cases of acute gastroenteritis
is associated with norovirus. Norovirus is responsible for
approximately 685 million cases of gastroenteritis every year. -
Globally, norovirus is estimated to cause approximately 200,000 deaths
annually, with at least 50,000 being children, mainly in developing
countries. -
There are four clinical candidates in development for norovirus; two
in Phase I and two in Phase II. The majority of clinical candidates
currently in the pipeline for norovirus are vaccines. These are
administered via the oral, intranasal, and intramuscular routes. -
Topline Phase IIb trial results for Monovalent Norovirus VLP Vaccine
is the only high-impact upcoming event for drugs in the norovirus
space. -
The overall likelihood of approval of a Phase I antiviral asset is
16.2%, and the average probability a drug advances from Phase III is
75.9%. Drugs, on average, take 8.6 years from Phase I to approval,
compared to 9 years in the overall infectious disease space. -
The clinical trials distribution across Phase I-III indicates that the
vast majority of trials for norovirus have been in the early and
mid-phases of development, with 91% of trials in Phase I-II, and only
9% in Phase III. -
Takeda has the highest number of completed and planned clinical trials
for norovirus, with eight trials in each category. Takeda also leads
industry sponsors with by far the highest overall number of clinical
trials for norovirus, followed by Vaxart.
Key Topics Covered
OVERVIEW
KEY TAKEAWAYS
DISEASE BACKGROUND
TREATMENT
EPIDEMIOLOGY
Norovirus outbreaks
Challenges for vaccine development
PIPELINE DRUGS
KEY UPCOMING EVENTS
PROBABILITY OF SUCCESS
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events
BIBLIOGRAPHY
APPENDIX
LIST OF FIGURES
Figure 1: Overview of pipeline drugs for norovirus in the US
Figure 2: Pipeline drugs for norovirus, by company
Figure 3: Pipeline drugs for norovirus, by drug type
Figure 4: Pipeline drugs for norovirus, by classification
Figure 5: Key upcoming events in norovirus
Figure 6: Probability of success in the norovirus pipeline
Figure 7: Clinical trials in norovirus
Figure 8: Top 10 drugs for clinical trials in norovirus
Figure 9: Top 10 companies for clinical trials in norovirus
Figure 10: Norovirus trials status
Figure 11: Norovirus trials sponsors, by phase
LIST OF TABLES
Table 1: Pipeline drugs for norovirus in the US
For more information about this report visit https://www.researchandmarkets.com/r/yf3qp4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Gastrointestinal
Drugs